The invention concerns phenoxypropanolamines of formula (I)
##STR1##
in which R.sub.1 represents a hydrogen, a group --S(O).sub.z --(C.sub.1
-C.sub.4)alk-R', (R' being H, phenyl or (C.sub.1 -C.sub.4)alkoxy),
--NHSO.sub.2 --(C.sub.1 -C.sub.4)alk or NHCO(C.sub.1 -C.sub.4)alk; m and n
are each independently 0, 1 or 2; R.sub.2 and R.sub.3 independently
represent a hydrogen, a (C.sub.5 -C.sub.6)alkyl, (C.sub.3
-C.sub.6)cycloalkyl, (C.sub.1 -C.sub.4)alkoxy, hydrogen(C.sub.1
-C.sub.4)alkoxy-(C.sub.1 -C.sub.4)alkyl, mono- or di(C.sub.1
-C.sub.4)alkamino(C.sub.1 -C.sub.4)alkyl, pyrrolidino(C.sub.1
-C.sub.4)alkyl, phenylamino or (C.sub.2 -C.sub.4)alkenyl group, an
aromatic or heteroaromatic group optionally substituted with a group
R.sub.4, an aralkyl or heteroaralkyl group optionally substituted with a
group R.sub.4, R.sub.2 and R.sub.3 can also together constitute a
saturated or unsaturated ring of 3 to 8 atoms possibly bearing a (C.sub.1
-C.sub.4)alkyl, amino (C.sub.1 -C.sub.4)alkyl, carbamoyl or benzyl
substituent; R.sub.4 represents a hydrogen or a halogen, or a group
--CO(C.sub.1 -C.sub.4)alk or a group --NHSO.sub.2 --(C.sub.1 -C.sub.4)alk;
a group (C.sub.1 -C.sub.4)alk, a group (C.sub.1 -C.sub.4)alkoxy, a
halogen, --COOH, --COO(C.sub.1 -C.sub.4)alk, --CN, --CONR.sub.3 R.sub.4,
--NO.sub.2, --SO.sub.2 NH.sub.2 or --NHSO.sub.2 (C.sub.1 -C.sub.4)alk; z
is 1 or 2; and the salts or solvates thereof. The compounds have agonist
activity toward .beta.-3 adrenergic receptors.
La invención se refiere a los phenoxypropanolamines del ## en los cuales R.sub.1 representa un hidrógeno, un grupo -- S(O).sub.z del ## STR1 del fórmula (i) -- (C.sub.1 - C.sub.4)alk-R ', (R ' que es H, fenilo o (C.sub.1 - C.sub.4)alkoxy), -- NHSO.sub.2 -- (C.sub.1 - C.sub.4)alk o NHCO(C.sub.1 - C.sub.4)alk; m y n son cada uno independientemente 0, 1 o 2; R.sub.2 y R.sub.3 representan independientemente un hidrógeno, a (C.sub.5 - C.sub.6)alkyl, (C.sub.3 - C.sub.6)cycloalkyl, (C.sub.1 - C.sub.4)alkoxy, hydrogen(C.sub.1 - C.sub.4)alkoxy-(C.sub.1 - C.sub.4)alkyl, mono o di(C.sub.1 - C.sub.4)alkamino(C.sub.1 - C.sub.4)alkyl, pyrrolidino(C.sub.1 - C.sub.4)alkyl, phenylamino o (C.sub.2 - el grupo de C.sub.4)alkenyl, un grupo aromático o heteroaromatic substituido opcionalmente con un grupo R.sub.4, un aralkyl o un grupo del heteroaralkyl substituido opcionalmente con un grupo R.sub.4, R.sub.2 y R.sub.3 pueden también juntos constituir un anillo saturado o no saturado de 3 a 8 átomos que llevan posiblemente a (C.sub.1 - C.sub.4)alkyl, amino (C.sub.1 - C.sub.4)alkyl, carbamoyl o sustituto benzyl; R.sub.4 representa a un hidrógeno o a un halógeno, o a grupo -- CO(C.sub.1 - C.sub.4)alk o un grupo -- NHSO.sub.2 -- (C.sub.1 - C.sub.4)alk; un grupo (C.sub.1 - C.sub.4)alk, un grupo (C.sub.1 - C.sub.4)alkoxy, un halógeno, -- cooh, -- COO(C.sub.1 - C.sub.4)alk, --CN, -- CONR.sub.3 R.sub.4, -- NO.sub.2, -- SO.sub.2 NH.sub.2 o -- NHSO.sub.2 (C.sub.1 - C.sub.4)alk; z es 1 o 2; y las sales o los solvates de eso. Los compuestos tienen actividad del agonista hacia los receptores adrenergic del beta.-3.
